- Home
- UFG vs LCTX Comparison
UFG vs LCTX Comparison
Compare UFG & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFG
- LCTX
- Stock Information
- Founded
- UFG 2021
- LCTX 1990
- Country
- UFG Singapore
- LCTX United States
- Employees
- UFG N/A
- LCTX N/A
- Industry
- UFG Oil Refining/Marketing
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UFG Energy
- LCTX Health Care
- Exchange
- UFG Nasdaq
- LCTX Nasdaq
- Market Cap
- UFG 136.4M
- LCTX 127.7M
- IPO Year
- UFG 2025
- LCTX N/A
- Fundamental
- Price
- UFG $4.39
- LCTX $0.68
- Analyst Decision
- UFG
- LCTX Strong Buy
- Analyst Count
- UFG 0
- LCTX 4
- Target Price
- UFG N/A
- LCTX $4.50
- AVG Volume (30 Days)
- UFG 166.1K
- LCTX 1.2M
- Earning Date
- UFG 01-01-0001
- LCTX 03-06-2025
- Dividend Yield
- UFG N/A
- LCTX N/A
- EPS Growth
- UFG N/A
- LCTX N/A
- EPS
- UFG 0.02
- LCTX N/A
- Revenue
- UFG $130,669,390.00
- LCTX $8,719,000.00
- Revenue This Year
- UFG N/A
- LCTX N/A
- Revenue Next Year
- UFG N/A
- LCTX $41.15
- P/E Ratio
- UFG $225.13
- LCTX N/A
- Revenue Growth
- UFG 129.69
- LCTX N/A
- 52 Week Low
- UFG $3.82
- LCTX $0.48
- 52 Week High
- UFG $5.10
- LCTX $1.61
- Technical
- Relative Strength Index (RSI)
- UFG N/A
- LCTX 53.39
- Support Level
- UFG N/A
- LCTX $0.58
- Resistance Level
- UFG N/A
- LCTX $0.73
- Average True Range (ATR)
- UFG 0.00
- LCTX 0.05
- MACD
- UFG 0.00
- LCTX 0.00
- Stochastic Oscillator
- UFG 0.00
- LCTX 50.67
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.